TEL AVIV, Israel, March 14, 2018 /PRNewswire/ -- BioLineRx
Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
biopharmaceutical company focused on oncology and immunology,
announced today that its Chief Executive Officer, Philip Serlin, will present a company update at
the 28th Annual Oppenheimer Healthcare Conference on
Tuesday, March 20, 2018 at
8:35 a.m. (EDT). The conference
will be held at the Westin Grand Central Hotel in New York, NY.
A live webcast of the presentation will be available on
BioLineRx's website. A replay will be available one hour after the
presentation ends and will be accessible for three months following
the presentation.
About BioLineRx
BioLineRx is a clinical-stage
biopharmaceutical company focused on oncology and immunology. The
Company in-licenses novel compounds, develops them through
pre-clinical and/or clinical stages, and then partners with
pharmaceutical companies for advanced clinical development and/or
commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase
2b study as an AML consolidation
treatment and has initiated a Phase 3 study in stem cell
mobilization for autologous transplantation; and AGI-134, an
immunotherapy treatment in development for multiple solid tumors,
which is expected to initiate a first-in-man study in mid-2018. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the US and Canada), on the basis
of which the Company is carrying out a Phase 2a study in pancreatic
cancer using the combination of BL-8040 and Merck's KEYTRUDA®; and
a collaboration agreement with Genentech, a member of the Roche
Group, to investigate the combination of BL-8040 and Genentech's
atezolizumab in several Phase 1b/2
studies for multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the
Company's website at www.biolinerx.com, where you can review the
Company's SEC filings, press releases, announcements and events.
BioLineRx industry updates are also regularly updated on Facebook,
Twitter, and LinkedIn.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-646-863-6274
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com
View original
content:http://www.prnewswire.com/news-releases/biolinerx-to-present-at-the-28th-annual-oppenheimer-healthcare-conference-300613777.html
SOURCE BioLineRx Ltd.